Desvenlafaxine
Product Images NDC 68071-2704

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 68071-2704). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2704 3)

This is a medication label for Desvenlafaxine 50mg tablets. It contains information such as the lot number, manufacturer NDC, exp. date, and serial number. The label also includes a warning to keep the medication out of reach of children, and a note to store it at a controlled temperature of 68-77°F. It provides instructions to see the manufacturer's label for a full list of ingredients, and to call a doctor for medical advice about side effects, with a phone number to report side effects to the FDA.*

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

The text provides information on the impact of renal and hepatic impairment and population description on PK. The geometric mean ratios (90% CI) of Cmax and AUC for different levels of renal and hepatic impairment are given. Also, the impact of age and gender on Cmax and AUC is presented. Therefore, the text might be useful in understanding the pharmacokinetics of a particular drug in different populations and conditions.*

FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

This text provides information on the change due to PK and CYP3A4 inhibitors such as ketoconazole. The geometric mean ratio with a 30% confidence level is also mentioned. There is information on the change in Cmax (maximum concentration) and AUC (area under the curve) for ketoconazole compared to the reference. However, as no context or further information is given, it is not clear what study or drug is being referred to.*

FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

FDA Label Image

Figure 4 (Desvenlafaxine Image4)

FDA Label Image

Figure 5 (Desvenlafaxine Image5)

The text shows a chart that indicates the estimated proportion of patients with a relapse and time to relapse in days from randomization. The chart compares Desvenlafaxine Extended-Release Tablets against Placebo. No additional information is available for interpretation.*

FDA Label Image

Structure (Desvenlafaxine Structure1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.